ClinicalTrials.gov API v2 · 登记更新· National Cancer Institute (NCI)·· 2 天前精选
肿瘤学：Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
AI 导读
原文摘录：This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory).
关注理由
这条肿瘤学内容涉及相关临床或研究问题，建议查看原文中的方法与适用范围。
来源：ClinicalTrials.gov API v2 · 登记更新 · clinicaltrials.gov